Evidence map›Paper›PMID 41857476›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Correlation of the expression of mismatch repair proteins, CDX2, and SATB2 with the clinicopathological parameters of patients with colorectal carcinoma.

Asem Shalaby, Heba Hany, Ahmed M Ramez, Islam H Metwally, Saleh S Elbalka, Ahmed M Fareed, Mohammad Zuhdy, Amany Hassan

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Asem ShalabyPathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. asemali444@yahoo.com.ORCID http://orcid.org/0000-0001-8032-2306
Heba HanyPathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed M RamezMedical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt.
Islam H MetwallySurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt.
Saleh S ElbalkaSurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt.
Ahmed M FareedSurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt.
Mohammad ZuhdySurgical Oncology Department, Oncology Center, Mansoura University, Mansoura, Egypt.
Amany HassanPathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutations in mismatch repair (MMR) genes play a crucial role in the pathogenesis of colorectal carcinoma (CRC), accounting for 10% to 15% of sporadic cases and up to 90% of hereditary non-polyposis cases. Reduced expression of the two transcription factors CDX2 and SATB2 has been linked to poor patient survival. The primary objective of this study was to evaluate the expression of mismatch repair proteins (MLH1, MSH2, MSH6, PMS2), along with CDX2 and SATB2, in relation to clinicopathologic characteristics and the survival outcome. MATERIAL AND

methodsThe study included 97 CRC patients with colectomy specimens received in the Pathology Department at Mansoura University during the period from 2011 to 2015. Immunohistochemistry for MLH1, MSH2, MSH6, PMS2, CDX2, and SATB2 was applied to tissue microarrays constructed from the patients' paraffin blocks.

resultsOut of the 97 CRC patients examined, 38.1% (n = 37) showed MMR deficiency, whereas 61.9% (n = 60) showed intact MMR expression. Twenty-one cases showed combined loss of two proteins: MLH1/PMS2 (n = 15) and MSH2/MSH6 (n = 6), while 13 cases showed loss of only one protein. A significant correlation between MMR deficiency and the patient gender, the right-sided location, and the low score of tumor-budding was noted (p-values of 0.045, 0.002, and 0.001, respectively). The overall MMR deficiency showed no statistically significant association with SATB2 expression score, while isolated MSH2 deficiency showed a significant association with SATB2 expression (p = 0.004). The disease-free survival (DFS) and overall survival (OAS) showed no significant association with MMR deficiency, CDX2, and SATB2 expression scores. A shorter DFS was noted with older age and rectal location (p = , p = .,, respectively), while shorter OAS was noted with older age and high tumor-budding (p = 0.046, p = 0.001, respectively).

conclusionThe MMR deficiency showed a significant association with the male gender, the right-sided location, and the low score of tumor-budding, and this may influence the prognosis and management plans. The relation between loss of SATB2, CDX2, and MMR protein expression needs further studies to be validated as a potential pathogenetic mechanism and as promising therapeutic targets.

Indexed as

Biomarkers, TumorCDX2 Transcription FactorColorectal NeoplasmsDNA Mismatch RepairMatrix Attachment Region Binding ProteinsTranscription FactorsAdultAgedAged, 80 and overDNA-Binding ProteinsFemaleHumansImmunohistochemistryMaleMiddle AgedMismatch Repair Endonuclease PMS2Biomarkers, TumorCDX2 protein, humanCDX2 Transcription FactorDNA-Binding ProteinsMatrix Attachment Region Binding ProteinsMismatch Repair Endonuclease PMS2MutL Protein Homolog 1SATB2 protein, humanTranscription FactorsColorectal cancerImmunohistochemistryMismatch repair proteins

Identifiers

PMID41857476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.